PD
CADL icon

Point72 (DIFC)’s Candel Therapeutics CADL Stock Holding History

Point72 (DIFC)’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-146
Closed -$740 – 1235
2025
Q2 		$740 Buy
+146
New +$751 ﹤0.01% 1444
2024
Q3 		– Sell
-4,927
Closed -$30.5K – 1482
2024
Q2 		$30.5K Buy
+4,927
New +$37K ﹤0.01% 1170

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Point72 (DIFC)'s CADL Position: Q3 2025 in Review

Point72 (DIFC) sold out of Candel Therapeutics (CADL) in Q3 2025, closing a stake of 146 shares — an estimated $740 sold.

Point72 (DIFC) first reported a position in CADL in Q2 2024 and held it in 2 quarters. The position peaked at $30.5K in Q2 2024. 81 funds tracked by Wall St. Rank hold CADL as of Q3 2025.

  • Point72 (DIFC) reported no remaining Candel Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 146 Candel Therapeutics shares in Q3 2025, an estimated $740.
  • Point72 (DIFC) first reported a position in Candel Therapeutics in Q2 2024 and held it in 2 quarters.
  • Point72 (DIFC)'s Candel Therapeutics position peaked at $30.5K in Q2 2024.
  • 81 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.